BioTechne Corp (TECH)
(Delayed Data from NSDQ)
$80.60 USD
+1.93 (2.45%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $80.59 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for BioTechne Corp falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 204 | 247 | 232 | 271 |
Receivables | NA | 218 | 195 | 145 | 123 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 172 | 141 | 117 | 103 |
Other Current Assets | NA | 27 | 23 | 17 | 24 |
Total Current Assets | NA | 621 | 606 | 511 | 521 |
Net Property & Equipment | NA | 226 | 223 | 208 | 177 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 1,407 | 1,354 | 1,459 | 1,245 |
Deposits & Other Assets | NA | 285 | 47 | 12 | 14 |
Total Assets | NA | 2,639 | 2,295 | 2,263 | 2,028 |
Liabilities & Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 26 | 34 | 29 | 23 |
Current Portion Long-Term Debt | NA | 0 | 13 | 13 | 13 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 52 | 80 | 67 | 40 |
Income Taxes Payable | NA | 12 | 13 | 5 | 2 |
Other Current Liabilities | NA | 28 | 25 | 27 | 19 |
Total Current Liabilities | NA | 129 | 176 | 152 | 107 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 89 | 99 | 93 | 101 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 350 | 243 | 329 | 344 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 11 | 17 | 50 | 27 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 672 | 594 | 692 | 646 |
Shareholders Equity | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 2 | 0 | 0 | 0 |
Capital Surplus | NA | 722 | 654 | 534 | 421 |
Retained Earnings | NA | 1,309 | 1,123 | 1,085 | 1,057 |
Other Equity | NA | -66 | -76 | -49 | -97 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 1,967 | 1,701 | 1,571 | 1,381 |
Total Liabilities & Shareholder's Equity | NA | 2,639 | 2,295 | 2,263 | 2,028 |
Total Common Equity | 0 | 1,967 | 1,701 | 1,571 | 1,381 |
Shares Outstanding | 157.50 | 157.40 | 156.90 | 155.50 | 152.80 |
Book Value Per Share | 0.00 | 12.49 | 10.84 | 10.10 | 9.04 |
Fiscal Year End for BioTechne Corp falls in the month of June.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 145 | 136 | 149 | 204 |
Receivables | NA | 228 | 207 | 205 | 218 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 180 | 181 | 186 | 172 |
Other Current Assets | NA | 58 | 67 | 52 | 27 |
Total Current Assets | NA | 611 | 591 | 591 | 621 |
Net Property & Equipment | NA | 244 | 234 | 232 | 226 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 1,497 | 1,531 | 1,548 | 1,407 |
Deposits & Other Assets | NA | 272 | 274 | 282 | 285 |
Total Assets | NA | 2,721 | 2,731 | 2,755 | 2,639 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 29 | 32 | 28 | 26 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 62 | 50 | 51 | 52 |
Income Taxes Payable | NA | 12 | 7 | 6 | 12 |
Other Current Liabilities | NA | 34 | 34 | 31 | 28 |
Total Current Liabilities | NA | 150 | 135 | 128 | 129 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 64 | 72 | 83 | 89 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 389 | 447 | 440 | 350 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 17 | 9 | 11 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 707 | 767 | 758 | 672 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 2 | 2 | 2 | 2 |
Capital Surplus | NA | 790 | 764 | 747 | 722 |
Retained Earnings | NA | 1,298 | 1,261 | 1,328 | 1,309 |
Other Equity | NA | -75 | -64 | -78 | -66 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 2,014 | 1,964 | 1,998 | 1,967 |
Total Liabilities & Shareholder's Equity | NA | 2,721 | 2,731 | 2,755 | 2,639 |
Total Common Equity | 0 | 2,014 | 1,964 | 1,998 | 1,967 |
Shares Outstanding | 157.50 | 157.10 | 158.10 | 158.20 | 157.40 |
Book Value Per Share | 0.00 | 12.82 | 12.42 | 12.63 | 12.49 |